Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?

Vaccine

Volumn 28, Issue 37, 2010, Pages 5947-5951

  Levy, Vivian ^a,b   Evans, Jennifer L ^c   Stein, Ellen S ^c   Davidson, Peter J ^d   Lum, Paula J ^c   Hahn, Judith A ^c   Page, Kimberly ^c  

^a San Mateo County Health Department   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C; Injection drug use; Vaccine trial

Indexed keywords

HEPATITIS C VACCINE; PLACEBO; HEPATITIS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH SURVEY; HEPATITIS C; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; PATIENT PARTICIPATION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; MALE; PATIENT PARTICIPATION; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 77955512996     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.006     Document Type: Article

References (27)

1. Barrera J.M., Bruguera M., Ercilla M.G., Gil C., Celis R., Gil M.P., et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995, 21(3):639-644.
2. Perz J.F., Alter M.J. The coming wave of HCV related liver disease: dilemmas and challenges. Journal of Hepatology 2006, 44:441-443.
3. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
4. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases 2002, 186(11):1558-1564.
5. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 2002, 155(7):645-653.
6. Des Jarlais D.C., Diaz T., Perlis T., Vlahov D., Maslow C., Latka M., et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. American Journal of Epidemiology 2003, 157(5):467-471.
7. Garten R.J., Lai S., Zhang J., Liu W., Chen J., Vlahov D., et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology 2004, 33(1):182-188.
8. Wasley A., Grytdal S., Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. Morbidity Mortality Weekly Reports Surveillance Summaries 2008, 57.
9. Hurley S.F., Joeely D.J., Kaldor J.M. Effectiveness of needle exchange programmes for prevention of HIV infection. Lancet 1997, 349:1797-1800.
10. Hahn J., Page-Shafer K., Lum P., Ochoa K., Moss A. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001, 34:180-187.
11. Page K., Hahn J.A., Evans J., Shiboski S., Lum P., Delwart E., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution and reinfection. Journal of Infectious Diseases 2009, 200:1216-1226.
12. Hagan H., Latka M.H., Campbell J.V., Golub E.T., Garfein R.S., Thomas D.A., et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clinical Infectious Diseases 2006, 42(5):669-672.
13. Page-Shafer K., Hahn J.A., Lum P.J. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007, 21(14):1967-1969.
14. Simmonds P. Genetic diversity and evolution of hepatitis C virus. Journal of General Virology 2004, 85:3173-3188.
15. Hu D.J., Vitek C.R., Bartholow B., Mastro T.D. Key issues for a potential human immunodeficiency virus vaccine. Clinical Infectious Diseases 2003, 36(5):638-644.
16. Buchbinder S.P., Metch B., Holte S.E., Scheer S., Coletti A., Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. Journal of Acquired Immune Deficiency Syndrome 2004, 36(1):604-612.
17. Koblin B.A., Heagerty P., Sheon A., Buchbinder S., Celum C., Douglas J.M., et al. Readiness of high risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998, 12(7):785-793.
18. Koblin B.A., Holte S., Lenderking B., Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. Journal of Acquired Immune Deficiency Syndrome 2000, 24(5):451-457.
19. Coletti A.S., Heagerty P., Sheon A.R., Gross M., Koblin B.A., Metzger D.S., et al. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. Journal of Acquired Immune Deficiency Syndrome 2003, 32(2):161-169.
20. Sullivan M. Moving candidate vaccines into development from research: lessons from HIV. Immunology and Cell Biology 2009, 87:366-370.
21. Etcheverry M.F., de Lazzari E., Fuchs J.D., Merono M., Sierra E., Del Romero J., et al. Pilot study assessing HIV vaccine trial readiness among female sex workers, injection and non-injection drug users, and men who have sex with men in Spain. AIDS Behavior 2010, 14:607-617.
22. Meyers K., Metzger D.S., Navaline H., Woody G.E., McLellan A.T. HIV vaccine trials: will intravenous drug users enroll?. American Journal of Public Health 1994, 84(5):761-766.
23. Dolan K.A., Shearer J., White B., Zhou J., Kaldor J., Wodak A.D. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005, 100(6):820-828.
24. Gibson D.R., Flynn N.M., Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001, 15:1329-1341.
25. Wood E., Tyndall M.W., Zhang R., Stoltz J.A., Lai C., Montaner J.S., et al. Attendance at supervised injecting facilities and use of detoxification services. New England Journal of Medicine 2006, 354:2512-2514.
26. Hagan H., Thiede H., Des Jarlais D. Hepatitis C infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004, 15:543-549.
27. Judd A., Hickman M., Jones S., McDonald T., Parry J.V., Stimson G.V., et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 2005, 330(7481):24-25.